Targeting autophagy in breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 224-240

  Maycotte, Paola ^a   Thorburn, Andrew ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; Breast cancer; Cancer; Chemotherapy; Estrogen receptor; HER2; Radiation; Triple negative breast cancer

Indexed keywords

EID: 84923139164     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.224     Document Type: Review

References (125)

1. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M, Korolchuk VI, Lichtenberg M, Luo S, Massey DC, Menzies FM, Moreau K, Narayanan U, Renna M, Siddiqi FH, Underwood BR, Winslow AR, Rubinsztein DC. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010; 90: 1383-1435 [PMID: 20959619 DOI: 10.1152/physrev.00030.2009]
2. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 2012; 11: 709-730 [PMID: 22935804 DOI: 10.1038/nrd3802]
3. Debnath J. The multifaceted roles of autophagy in tumorsimplications for breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 173-187 [PMID: 21779879 DOI: 10.1007/s10911-011-9223-3]
4. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12: 401-410 [PMID: 22534666 DOI: 10.1038/nrc3262]
5. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G. Autophagydependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-1577 [PMID: 22174255 DOI: 10.1126/science.1208347]
6. Wei H, Wei S, Gan B, Peng X, Zou W, Guan JL. Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev 2011; 25: 1510-1527 [PMID: 21764854 DOI: 10.1101/gad.2051011]
7. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007; 8: 931-937 [PMID: 17712358 DOI: 10.1038/nrm2245]
8. Lorin S, Hamaï A, Mehrpour M, Codogno P. Autophagy regulation and its role in cancer. Semin Cancer Biol 2013; 23: 361-379 [PMID: 23811268 DOI: 10.1016/j.semcancer.2013.06.007]
9. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069-1075 [PMID: 18305538 DOI: 10.1038/nature06639]
10. Shen HM, Codogno P. Autophagic cell death: Loch Ness monster or endangered species? Autophagy 2011; 7: 457-465 [PMID: 21150268]
11. Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L, Zhu WG. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2010; 12: 665-675 [PMID: 20543840 DOI: 10.1038/ncb2069]
12. Clarke PG, Puyal J. Autophagic cell death exists. Autophagy 2012; 8: 867-869 [PMID: 22652592 DOI: 10.4161/auto.20380]
13. Reef S, Zalckvar E, Shifman O, Bialik S, Sabanay H, Oren M, Kimchi A. A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol Cell 2006; 22: 463-475 [PMID: 16713577 DOI: 10.1016/j.molcel.2006.04.014]
14. Shen S, Kepp O, Kroemer G. The end of autophagic cell death? Autophagy 2012; 8: 1-3 [PMID: 22082964 DOI: 10.4161/auto.8.1.16618]
15. Maycotte P, Thorburn A. Autophagy and cancer therapy. Cancer Biol Ther 2011; 11: 127-137 [PMID: 21178393]
16. Liu Y, Shoji-Kawata S, Sumpter RM, Wei Y, Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ, Shaw SY, Clarke PG, Puyal J, Levine B. Autosis is a Na+, K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci USA 2013; 110: 20364-20371 [PMID: 24277826 DOI: 10.1073/pnas.1319661110]
17. Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol 2013; 15: 713-720 [PMID: 23817233 DOI: 10.1038/ncb2788]
18. Föllgrabe J, Klionsky DJ, Joseph B. The return of the nucleus: Transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol 2014; 15: 65-74 [PMID: 24326622 DOI: 10.1038/nrm3716]
19. Jiang P, Mizushima N. Autophagy and human diseases. Cell Res 2014; 24: 69-79 [PMID: 24323045 DOI: 10.1038/cr.2013.161]
20. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402: 672-676 [PMID: 10604474 DOI: 10.1038/45257]
21. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100: 15077-15082 [PMID: 14657337 DOI: 10.1073/pnas.2436255100]
22. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820 [PMID: 14638851 DOI: 10.1172/JCI20039]
23. Laddha SV, Ganesan S, Chan CS, White E. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res 2014; 12: 485-490 [PMID: 24478461 DOI: 10.1158/1541-7786.MCR-13-0614]
24. Mariño G, Salvador-Montoliu N, Fueyo A, Knecht E, Mizushima N, López-Otín C. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem 2007; 282: 18573-18583 [PMID: 17442669 DOI: 10.1074/jbc.M701194200]
25. Jin S. Autophagy, mitochondrial quality control, and oncogenesis. Autophagy 2006; 2: 80-84 [PMID: 16874075]
26. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137: 1062-1075 [PMID: 19524509 DOI: 10.1016/j.cell.2009.03.048]
27. Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, Liang C, Jung JU, Cheng JQ, Mulé JJ, Pledger WJ, Wang HG. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007; 9: 1142-1151 [PMID: 17891140 DOI: 10.1038/ncb1634]
28. Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, Jung JU. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol 2006; 8: 688-699 [PMID: 16799551 DOI: 10.1038/ncb1426]
29. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011; 25: 795-800 [PMID: 21498569 DOI: 10.1101/gad.2016211]
30. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42 [PMID: 18191218 DOI: 10.1016/j.cell.2007.12.018]
31. Maiuri MC, Criollo A, Kroemer G. Crosstalk between apoptosis and autophagy within the Beclin 1 interactome. EMBO J 2010; 29: 515-516 [PMID: 20125189 DOI: 10.1038/emboj.2009.377]
32. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Norberg HV, Zhang T, Furuya T, Jin M, Zhu Z, Wang H, Yu J, Li Y, Hao Y, Choi A, Ke H, Ma D, Yuan J. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011; 147: 223-234 [PMID: 21962518 DOI: 10.1016/j.cell.2011.08.037]
33. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, White E. Autophagy suppresses progression of K-rasinduced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27: 1447-1461 [PMID: 23824538 DOI: 10.1101/gad.219642.113]
34. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10: 51-64 [PMID: 16843265 DOI: 10.1016/j.ccr.2006.06.001]
35. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008; 19: 797-806 [PMID: 18094039 DOI: 10.1091/mbc.E07-10-1092]
36. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V, Coller HA, Dipaola RS, Gelinas C, Rabinowitz JD, White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25: 460-470 [PMID: 21317241 DOI: 10.1101/gad.2016311]
37. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011; 22: 165-178 [PMID: 21119005 DOI: 10.1091/mbc.E10-06-0500]
38. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dellantonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25: 717-729 [PMID: 21406549 DOI: 10.1101/gad.2016111]
39. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 2013; 3: 1272-1285 [PMID: 23965987 DOI: 10.1158/2159-8290. CD-13-0397]
40. Rosenfeldt MT, OPrey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, Anderson KI, Gottlieb E, Sansom OJ, Ryan KM. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504: 296-300 [PMID: 24305049 DOI: 10.1038/nature12865]
41. Elgendy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell 2011; 42: 23-35 [PMID: 21353614 DOI: 10.1016/j.molcel.2011.02.009]
42. Chen N, Eritja N, Lock R, Debnath J. Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in three-dimensional culture. Oncogene 2013; 32: 2543-2554 [PMID: 22777351 DOI: 10.1038/onc.2012.277]
43. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013
44. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 2009; 15: 6327-6340 [PMID: 19808870 DOI: 10.1158/1078-0432. CCR-09-1107]
45. Zhao JJ, Silver DP. Estrogen receptor-negative breast cancer: new insights into subclassification and targeting. Clin Cancer Res 2009; 15: 6309-6310 [PMID: 19825953 DOI: 10.1158/1078-0432.CCR-09-2010]
46. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70 [PMID: 23000897 DOI: 10.1038/nature11412]
47. Hudis CA, Gianni L. Triple-negative breast cancer: An unmet medical need. Oncologist 2011; 16 Suppl 1: 1-11 [PMID: 21278435 DOI: 10.1634/theoncologist.2011-S1-01]
48. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23 [PMID: 21147047 DOI: 10.1016/j.molonc.2010.11.003]
49. Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 2013; 10: 494-506 [PMID: 23881035 DOI: 10.1038/nrclinonc.2013.124]
50. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010; 15 Suppl 5: 39-48 [PMID: 21138954 DOI: 10.1634/theoncologist.2010-S5-39]
51. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334 [PMID: 17438091 DOI: 10.1158/1078-0432.CCR-06-1109]
52. Engebraaten O, Vollan HK, Børresen-Dale AL. Triplenegative breast cancer and the need for new therapeutic targets. Am J Pathol 2013; 183: 1064-1074 [PMID: 23920327 DOI: 10.1016/j.ajpath.2013.05.033]
53. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767 [PMID: 21633166 DOI: 10.1172/JCI45014]
54. Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol 2014; 141: 462-477 [PMID: 24619745 DOI: 10.1309/AJCPQN8GZ8SILKGN]
55. Austreid E, Lonning PE, Eikesdal HP. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opin Pharmacother 2014; 15: 681-700 [PMID: 24579888 DOI: 10.1517/146565 66.2014.885952]
56. Negri T, Tarantino E, Orsenigo M, Reid JF, Gariboldi M, Zambetti M, Pierotti MA, Pilotti S. Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes Cancer 2010; 49: 901-909 [PMID: 20589936 DOI: 10.1002/gcc.20798]
57. Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids 2013; 2: e121 [PMID: 24022053 DOI: 10.1038/mtna.2013.45]
58. Won KY, Kim GY, Kim YW, Song JY, Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol 2010; 41: 107-112 [PMID: 19762066 DOI: 10.1016/j.humpath.2009.07.006]
59. Oh S, Xiaofei E, Ni D, Pirooz SD, Lee JY, Lee D, Zhao Z, Lee S, Lee H, Ku B, Kowalik T, Martin SE, Oh BH, Jung JU, Liang C. Downregulation of autophagy by Bcl-2 promotes MCF7 breast cancer cell growth independent of its inhibition of apoptosis. Cell Death Differ 2011; 18: 452-464 [PMID: 20885445 DOI: 10.1038/cdd.2010.116]
60. Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S, Barnard N, Ganesan S, Karantza V, White E, Xia B. Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-Associated hereditary breast cancer. Cancer Discov 2013; 3: 894-907 [PMID: 23650262 DOI: 10.1158/2159-8290.CD-13-0011]
61. Jiang PD, Zhao YL, Deng XQ, Mao YQ, Shi W, Tang QQ, Li ZG, Zheng YZ, Yang SY, Wei YQ. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed Pharmacother 2010; 64: 609-614 [PMID: 20888174 DOI: 10.1016/j.biopha.2010.06.004]
62. Cook KL, Shajahan AN, Clarke R. Autophagy and en-docrine resistance in breast cancer. Expert Rev Anticancer Ther 2011; 11: 1283-1294 [PMID: 21916582 DOI: 10.1586/era.11.111]
63. Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT, Schoenlein PV. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 2008; 7: 2977-2987 [PMID: 18790778 DOI: 10.1158/1535-7163. MCT-08-0447]
64. Crawford AC, Riggins RB, Shajahan AN, Zwart A, Clarke R. Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-Associated necrosis. PLoS One 2010; 5: e8604 [PMID: 20062536 DOI: 10.1371/journal.pone.0008604]
65. Han J, Hou W, Lu C, Goldstein LA, Stolz DB, Watkins SC, Rabinowich H. Interaction between Her2 and Beclin-1 proteins underlies a new mechanism of reciprocal regulation. J Biol Chem 2013; 288: 20315-20325 [PMID: 23703612 DOI: 10.1074/jbc.M113.461350]
66. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 2009; 4: e6251 [PMID: 19606230 DOI: 10.1371/journal.pone.0006251]
67. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, López-Bonet E, Martin-Castillo B, Joven J, Menendez JA. The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep 2013; 3: 2469 [PMID: 23965851 DOI: 10.1038/srep02469]
68. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-Targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget 2012; 3: 1600-1614 [PMID: 23307622]
69. Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, Grishin NV, Peyton M, Minna J, Bhagat G, Levine B. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013; 154: 1269-1284 [PMID: 24034250 DOI: 10.1016/j.cell.2013.08.015]
70. Bese NS. Radiochemotherapy in the treatment of breast cancer. Clin Oncol (R Coll Radiol) 2009; 21: 532-535 [PMID: 19464156 DOI: 10.1016/j.clon.2009.04.005]
71. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19: 312-321 [PMID: 20382530 DOI: 10.1016/j.breast.2010.03.026]
72. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thörlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747 [PMID: 21709140 DOI: 10.1093/annonc/mdr304]
73. Sun WL, Chen J, Wang YP, Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011; 7: 1035-1044 [PMID: 21646864]
74. Sishi BJ, Loos B, van Rooyen J, Engelbrecht AM. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol 2013; 85: 124-134 [PMID: 23107818 DOI: 10.1016/j.bcp.2012.10.005]
75. Mackeh R, Perdiz D, Lorin S, Codogno P, Poös C. Autophagy and microtubules-new story, old players. J Cell Sci 2013; 126: 1071-1080 [PMID: 23620510 DOI: 10.1242/jcs.115626]
76. Veldhoen RA, Banman SL, Hemmerling DR, Odsen R, Simmen T, Simmonds AJ, Underhill DA, Goping IS. The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene 2013; 32: 736-746 [PMID: 22430212 DOI: 10.1038/onc.2012.92]
77. Köchl R, Hu XW, Chan EY, Tooze SA. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic 2006; 7: 129-145 [PMID: 16420522 DOI: 10.1111/j.1600-0854.2005.00368.x]
78. Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. J Biomed Res 2013; 27: 254-271 [PMID: 23885265 DOI: 10.7555/JBR.27.20130030]
79. Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012; 8: 200-212 [PMID: 22252008 DOI: 10.4161/auto.8.2.18554]
80. Bristol ML, Emery SM, Maycotte P, Thorburn A, Chakradeo S, Gewirtz DA. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 2013; 344: 544-552 [PMID: 23291713 DOI: 10.1124/jpet.112.199802]
81. Bristol ML, Di X, Beckman MJ, Wilson EN, Henderson SC, Maiti A, Fan Z, Gewirtz DA. Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3. Autophagy 2012; 8: 739-753 [PMID: 22498493 DOI: 10.4161/auto.19313]
82. Gewirtz DA, Hilliker ML, Wilson EN. Promotion of autophagy as a mechanism for radiation sensitization of breast tumor cells. Radiother Oncol 2009; 92: 323-328 [PMID: 19541381 DOI: 10.1016/j.radonc.2009.05.022]
83. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triplenegative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683-692 [PMID: 20877296 DOI: 10.1038/nrclinonc.2010.154]
84. Thomas S, Sharma N, Golden EB, Cho H, Agarwal P, Gaffney KJ, Petasis NA, Chen TC, Hofman FM, Louie SG, Schönthal AH. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett 2012; 325: 63-71 [PMID: 22664238 DOI: 10.1016/j.canlet.2012.05.030]
85. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 2009; 69: 4415-4423 [PMID: 19417138 DOI: 10.1158/0008-5472.CAN-08-2839]
86. Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, Bhalla KN. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triplenegative human breast cancer cells. Mol Cancer Ther 2012; 11: 973-983 [PMID: 22367781 DOI: 10.1158/1535-7163. MCT-11-0979]
87. Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 2008; 4: 669-679 [PMID: 18424910]
88. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905 [PMID: 20164920 DOI: 10.1038/nature08822]
89. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296 [PMID: 22439924 DOI: 10.1016/j.ccr.2012.03.003]
90. Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64: 937-946 [PMID: 21680574 DOI: 10.1136/jcp.2011.090456]
91. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735 [PMID: 21633165 DOI: 10.1172/JCI44745]
92. Guan JL, Simon AK, Prescott M, Menendez JA, Liu F, Wang F, Wang C, Wolvetang E, Vazquez-Martin A, Zhang J. Autophagy in stem cells. Autophagy 2013; 9: 830-849 [PMID: 23486312 DOI: 10.4161/auto.24132]
93. Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, Petricoin EF, Pastore L, Zaman S, Menezes G, Mize J, Johal J, Edmiston K, Liotta LA. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One 2010; 5: e10240 [PMID: 20421921 DOI: 10.1371/journal. pone.0010240]
94. Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer 2011; 11: 68-75 [PMID: 21150936 DOI: 10.1038/nrc2950]
95. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L, Menendez JA. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011; 10: 3871-3885 [PMID: 22127234 DOI: 10.4161/cc.10.22.17976]
96. Gong C, Bauvy C, Tonelli G, Yue W, Deloménie C, Nicolas V, Zhu Y, Domergue V, Marin-Esteban V, Tharinger H, Delbos L, Gary-Gouy H, Morel AP, Ghavami S, Song E, Codogno P, Mehrpour M. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2013; 32: 2261-2272, 2261-2272 [PMID: 22733132 DOI: 10.1038/onc.2012.252]
97. Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res 2014; 74: 2579-2590 [PMID: 24590058 DOI: 10.1158/0008-5472. CAN-13-3470]
98. Ko A, Kanehisa A, Martins I, Senovilla L, Chargari C, Dugue D, Mariño G, Kepp O, Michaud M, Perfettini JL, Kroemer G, Deutsch E. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 2014; 21: 92-99 [PMID: 24037090 DOI: 10.1038/cdd.2013.124]
99. He C, Levine B. The Beclin 1 interactome. Curr Opin Cell Biol 2010; 22: 140-149 [PMID: 20097051 DOI: 10.1016/j.ceb.2010.01.001]
100. Fu LL, Cheng Y, Liu B. Beclin-1: Autophagic regulator and therapeutic target in cancer. Int J Biochem Cell Biol 2013; 45: 921-924 [PMID: 23420005 DOI: 10.1016/j.biocel.2013.02.007]
101. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011; 18: 571-580 [PMID: 21311563 DOI: 10.1038/cdd.2010.191]
102. Criollo A, Niso-Santano M, Malik SA, Michaud M, Morselli E, Mariño G, Lachkar S, Arkhipenko AV, Harper F, Pierron G, Rain JC, Ninomiya-Tsuji J, Fuentes JM, Lavandero S, Galluzzi L, Maiuri MC, Kroemer G. Inhibition of autophagy by TAB2 and TAB3. EMBO J 2011; 30: 4908-4920 [PMID: 22081109 DOI: 10.1038/emboj.2011.413]
103. Niu TK, Cheng Y, Ren X, Yang JM. Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS Lett 2010; 584: 3519-3524 [PMID: 20638385 DOI: 10.1016/j.febslet.2010.07.018]
104. Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L, Wilkins AD, Sun Q, Pallauf K, MacDuff D, Huerta C, Virgin HW, Helms JB, Eerland R, Tooze SA, Xavier R, Lenschow DJ, Yamamoto A, King D, Lichtarge O, Grishin NV, Spector SA, Kaloyanova DV, Levine B. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013; 494: 201-206 [PMID: 23364696 DOI: 10.1038/nature11866]
105. Klionsky DJ, Baehrecke EH, Brumell JH, Chu CT, Codogno P, Cuervo AM, Debnath J, Deretic V, Elazar Z, Eskelinen EL, Finkbeiner S, Fueyo-Margareto J, Gewirtz D, Jäättelä M, Kroemer G, Levine B, Melia TJ, Mizushima N, Rubinsztein DC, Simonsen A, Thorburn A, Thumm M, Tooze SA. A comprehensive glossary of autophagy-related molecules and processes (2nd edition). Autophagy 2011; 7: 1273-1294 [PMID: 21997368 DOI: 10.4161/auto.7.11.17661]
106. Velikkakath AK, Nishimura T, Oita E, Ishihara N, Mizushima N. Mammalian Atg2 proteins are essential for autophagosome formation and important for regulation of size and distribution of lipid droplets. Mol Biol Cell 2012; 23: 896-909 [PMID: 22219374 DOI: 10.1091/mbc.E11-09-0785]
107. Radoshevich L, Murrow L, Chen N, Fernandez E, Roy S, Fung C, Debnath J. ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. Cell 2010; 142: 590-600 [PMID: 20723759 DOI: 10.1016/j.cell.2010.07.018]
108. Maskey D, Yousefi S, Schmid I, Zlobec I, Perren A, Friis R, Simon HU. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun 2013; 4: 2130 [PMID: 23945651 DOI: 10.1038/ncomms3130]
109. Lee IH, Kawai Y, Fergusson MM, Rovira II, Bishop AJ, Motoyama N, Cao L, Finkel T. Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science 2012; 336: 225-228 [PMID: 22499945 DOI: 10.1126/science. 1218395]
110. Betz C, Hall MN. Where is mTOR and what is it doing there? J Cell Biol 2013; 203: 563-574 [PMID: 24385483 DOI: 10.1083/jcb.201306041]
111. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J 2008; 410: 1-17 [PMID: 18215151 DOI: 10.1042/BJ20071427]
112. Bitto A, Lerner CA, Nacarelli T, Crowe E, Torres C, Sell C. p62/SQSTM1 at the interface of aging, autophagy, and disease. Age (Dordr) 2014; 36: 9626 [PMID: 24557832 DOI: 10.1007/s11357-014-9626-3]
113. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010; 12: 213-223 [PMID: 20173742 DOI: 10.1038/ncb2021]
114. Mardakheh FK, Auciello G, Dafforn TR, Rappoport JZ, Heath JK. Nbr1 is a novel inhibitor of ligand-mediated receptor tyrosine kinase degradation. Mol Cell Biol 2010; 30: 5672-5685 [PMID: 20937771 DOI: 10.1128/MCB.00878-10]
115. Sanli T, Steinberg GR, Singh G, Tsakiridis T. AMP-Activated protein kinase (AMPK) beyond metabolism: A novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther 2014; 15: 156-169 [PMID: 24100703 DOI: 10.4161/cbt.26726]
116. ORiordan MX, Bauler LD, Scott FL, Duckett CS. Inhibitor of apoptosis proteins in eukaryotic evolution and development: A model of thematic conservation. Dev Cell 2008; 15: 497-508 [PMID: 18854135 DOI: 10.1016/j.devcel.2008.09.012]
117. Guo L, Yang LY, Fan C, Chen GD, Wu F. Novel roles of Vmp1: inhibition metastasis and proliferation of hepatocellular carcinoma. Cancer Sci 2012; 103: 2110-2119 [PMID: 22971212 DOI: 10.1111/cas.12025]
118. Shiloh R, Bialik S, Kimchi A. The DAPK family: A structure-function analysis. Apoptosis 2014; 19: 286-297 [PMID: 24220854 DOI: 10.1007/s10495-013-0924-5]
119. Takahashi Y, Meyerkord CL, Wang HG. Bif-1/endophilin B1: A candidate for crescent driving force in autophagy. Cell Death Differ 2009; 16: 947-955 [PMID: 19265852 DOI: 10.1038/cdd.2009.19]
120. Thoresen SB, Pedersen NM, Liestøl K, Stenmark H. A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res 2010; 316: 3368-3378 [PMID: 20643123 DOI: 10.1016/j.yexcr.2010.07.008]
121. He S, Ni D, Ma B, Lee JH, Zhang T, Ghozalli I, Pirooz SD, Zhao Z, Bharatham N, Li B, Oh S, Lee WH, Takahashi Y, Wang HG, Minassian A, Feng P, Deretic V, Pepperkok R, Tagaya M, Yoon HS, Liang C. PtdIns(3)P-bound UVRAG coordinates Golgi-ER retrograde and Atg9 transport by differential interactions with the ER tether and the beclin 1 complex. Nat Cell Biol 2013; 15: 1206-1219 [PMID: 24056303 DOI: 10.1038/ncb2848]
122. Nazio F, Cecconi F. mTOR, AMBRA1, and autophagy: An intricate relationship. Cell Cycle 2013; 12: 2524-2525 [PMID: 23907135 DOI: 10.4161/cc.25835]
123. Fimia GM, Corazzari M, Antonioli M, Piacentini M. Ambra1 at the crossroad between autophagy and cell death. Oncogene 2013; 32: 3311-3318 [PMID: 23069654 DOI: 10.1038/onc.2012.455]
124. Kang R, Zhang Q, Zeh HJ, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013; 19: 4046-4057 [PMID: 23723299 DOI: 10.1158/1078-0432.CCR-13-0495]
125. Chang NC, Nguyen M, Bourdon J, Risse PA, Martin J, Danialou G, Rizzuto R, Petrof BJ, Shore GC. Bcl-2-Associated autophagy regulator Naf-1 required for maintenance of skeletal muscle. Hum Mol Genet 2012; 21: 2277-2287 [PMID: 22343142 DOI: 10.1093/hmg/dds048]